Learn about Leqembi, Saudi Arabia's first approved treatment for Alzheimer’s disease, marking a major advancement in ...

TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Without the receptor, ADGRG1, the microglia barely nibbled on the toxic protein. Using a mouse model of Alzheimer's disease, ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Scientists at UCSF have uncovered how certain immune cells in the brain, called microglia, can effectively digest toxic ...

In a new study led by Yale University, researchers sought to illuminate apparent similarities between COVID brain fog and ...

The FDA cleared the use of the first approved blood test that can help diagnose Alzheimer’s disease. Learn more from U of U ...

Dementia can feel like a scary word but knowing what it means and how to spot the signs early can make a big difference.

UCSF researchers have identified ADGRG1, a microglial receptor that helps clear amyloid beta plaques in Alzheimer’s disease.

Microglia, a type of brain immune cell, can gobble up amyloid beta protein, which clumps together into toxic aggregates ...